Schwab Gisela 4
4 · EXELIXIS, INC. · Filed May 14, 2021
Insider Transaction Report
Form 4
EXELIXIS, INC.EXEL
Schwab Gisela
EVP & Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2021-05-13$1.90/sh+100,000$190,000→ 714,078 total - Sale
Common Stock
2021-05-13$25.38/sh−100,000$2,538,000→ 614,078 total - Exercise/Conversion
Option (right to buy)
2021-05-13−100,000→ 150,000 totalExercise: $1.90From: 2015-07-20Exp: 2022-02-04→ Common Stock (100,000 underlying)
Holdings
- 14,880(indirect: By 401(k))
Common Stock
Footnotes (5)
- [F1]Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 596 shares of common stock acquired on April 30, 2021, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan.
- [F2]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2021.
- [F3]Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.15 to $25.65. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
- [F4]Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 13, 2021.
- [F5]The option, representing the right to purchase a total of 250,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.